Drug Manufacturer Teva to Pay $523M to New York in Opioid Settlement
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Setback for Teva as court dismisses Copaxone lawsuit - PMLiVE
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Antitrust Action Targets Teva Multiple Sclerosis Drug | New Jersey Law Journal
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
Teva asks FDA to delay approval of Biogen's MS drug
Mylan Cuts Price of Generic Copaxone Offering by 60% | Ctech
Teva knocked as competition fears grow for MS drug | Financial Times
Patients struggle to afford medication for MS
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
EU says Teva blocked generics to MS drug Copaxone | pharmaphorum
Multiple Sclerosis Drugs Market to Reach US$ 39,289.5 Mn by
Multiple Sclerosis: New Treatments, Tough Decisions
Cummings and Welch Launch Investigation of Drug Companies' Skyrocketing Prices for MS Drugs | House Committee on Oversight and Reform
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Opioid maker Teva agrees to $4.25B settlement with Iowa, other states
Teva knocked as competition fears grow for MS drug | Financial Times
COPAXONE® | Medication to Treat Relapsing Multiple Sclerosis (RMS)
EU investigating Teva for blocking rivals to multiple sclerosis drug | Reuters
Health: The Price of Multiple Sclerosis Drugs Only Goes Up - Bloomberg
Teva Charged With Paying Kickbacks to Increase Sales of MS Drug - Health Law Offices of Anthony C. Vitale
Teva faces US government lawsuit over alleged kickbacks to spur Copaxone use | S&P Global Market Intelligence
Congressmen Investigate 'Shadow Pricing' of MS Drugs | RAPS
Teva upskilling of UK sterile site could lead to loss of 80 jobs
